One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Rubella Diagnostic Testing Market

[ 英語タイトル ] Rubella Diagnostic Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083609
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 113
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott
- Beckman Coulter Inc.
- Bio Rad Laboratories Inc.
- Biokit SA
- bioMérieux SA
- F. Hoffmann-La Roche Ltd
- Ortho Clinical Diagnostics
- Siemens Healthcare GmbH
- Thermo Fisher Scientific
- ZEUS Scientific Inc.

[Report Description]

The major factors for the growth of the rubella diagnostic testing market include the government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies, which are expected to boost the overall growth of the market over the forecast period.

There has been an increase in the number of incidences of rubella across the world. Rubella is an acute, contagious viral infection that causes a mild fever and rash illness in children and adults. Infection during pregnancy, especially during the first trimester, can result in miscarriage, stillbirth, fetal death, or infants with congenital malformations. According to the data published by the Centers for Disease Control and Prevention (CDC), rubella is a global health concern, and every year, more than 100,000 cases of congenital rubella syndrome (CRS) are reported, globally. A woman infected with rubella during the first three months of pregnancy has up to a 90% of chance of giving birth to a baby with congenital rubella syndrome.

On the other hand, as per the Global Vaccine Action Plan (GVAP) Assessment report, rubella control is lagging, with 42 countries yet to introduced the vaccine.

Key Market Trends

Enzyme Immunoassay Segment under Testing Technique Accounted for the Largest Share in the Global Market

- The detection of rubella-specific immunoglobulin M (IgM) in serum is the standard test for the rapid laboratory diagnosis of rubella.
- IgM testing is the most commonly performed testing technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies that are made by the immune system to kill the rubella virus, and these antibodies remain in the bloodstream for years.
- The segment is expected to account for the largest market share, owing to the rising incidences of rubella.

Asia-Pacific Accounted for the Highest Growth Rate in the Global Market

The Asia-Pacific segment, by geography, was found to register the fastest growth rate for the rubella diagnostic testing market, and is expected to show a similar trend over the forecast period, without significant fluctuations.

The Asia-Pacific region holds the highest market share, owing to the presence of larger untapped opportunities, a lack of awareness in some countries, and government initiatives to curb the disease incidence.

As per the Global Vaccine Action Plan (GVAP) Assessment report 2017, 42 countries have not yet introduced the vaccine, and two regions, Africa and the Eastern Mediterranean, have not yet set rubella elimination or control targets. Such regions are expected to face high incidences of rubella, which may further drive the growth of the market.

Competitive Landscape

The market studied is dominated by a few major players and most of the players present in the market are focusing on the development of new technologies to acquire the maximum market share. The presence of major market players, such as Abbott Laboratories, Bio Rad Laboratories Inc., BioMerieux SA, Siemens AG, and Thermo Fisher Scientific Inc., is increasing the overall competitive rivalry in the market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Initiatives to Curb Rubella Virus
4.2.2 Increasing Incidences of Rubella
4.2.3 Introduction of Advance Point-of-care Diagnostic Technologies
4.3 Market Restraints
4.3.1 Lack of Awareness among Developing Regions
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5.1 Testing Technique
5.1.1 Latex Agglutination
5.1.2 Enzyme Immunoassay (EIA)
5.1.3 Radioimmunoassay (RIA)
5.1.4 Fluorescent Immunoassay (FIA)
5.1.5 Other Testing Techniques
5.2 Application
5.2.1 Hospitals
5.2.2 Laboratories
5.2.3 Other Applications
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott
6.1.2 Beckman Coulter Inc.
6.1.3 Bio Rad Laboratories Inc.
6.1.4 Biokit SA
6.1.5 bioMérieux SA
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Ortho Clinical Diagnostics
6.1.8 Siemens Healthcare GmbH
6.1.9 Thermo Fisher Scientific
6.1.10 ZEUS Scientific Inc.




Recommended reports